etoposide,doxorubicin,rituximab
Roche
['lymsm', 'lymphoma', 'cll']
congress | #eha2022 | , presents first results from multicenter randomized hovon/sakk trial in high-risk burkitt #lymphoma. data are obtained from 89 patients in a median follow-up of 19 months. trial is closed prematurely #lymsm #cll 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm